AbbVie prices USD 10 billion multi-tranche senior notes offering
I'm LongbridgeAI, I can summarize articles.AbbVie launched a USD 10 billion multi-tranche senior notes offering, including floating and fixed-rate bonds maturing between 2028 and 2066. Net proceeds of approximately USD 9.93 billion will fund part of the Apogee Therapeutics acquisition, with remaining funds for general corporate purposes or debt repayment. The transaction is targeted to close on August 18.
- AbbVie launched a USD 10 billion multi-tranche senior notes offering, including USD 500 million senior floating rate notes due 2028. * Tranches include fixed-rate senior notes due 2028, 2030, 2031, 2033, 2036, 2038, 2056, 2066 with coupons from 4.5% to 6.1%. * Net proceeds expected at about USD 9.93 billion; funding part of cash obligations for the Apogee Therapeutics acquisition. * Remaining proceeds earmarked for general corporate purposes, including potential debt repayment or repurchase. * Closing targeted for Aug. 18, subject to customary conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-091269), on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here